Nirmatrelvir combined with ritonavir for preventing and treating COVID-19

Reis, S.; Popp, M.; Kuehn, R.; Metzendorf, M. I.; Gagyor, I.; Kranke, P.; Meybohm, P.; Skoetz, N.; Weibel, S.

Reis, S.; Popp, M.; Kuehn, R.; Metzendorf, M. I.; Gagyor, I.; Kranke, P.; Meybohm, P.; Skoetz, N.; Weibel, S..

Cochrane Database of Systematic Reviews ; 2022(4), 2022.

Article in English | EMBASE | ID: covidwho-1800404

ABSTRACT

ABSTRACT

Objectives:

This is a protocol for a Cochrane Review (intervention). The objectives are as follows. To assess the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid®) plus standard of care compared to standard of care with or without placebo, or any other proven intervention for treating COVID-19 and for preventing SARS-CoV-2 infection.

Keywords

comparative effectiveness; controlled study; coronavirus disease 2019; drug efficacy; drug safety; health care quality; human; prevention; review; placebo; ritonavir

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Cochrane Database of Systematic Reviews Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google